<DOC>
	<DOC>NCT01330290</DOC>
	<brief_summary>The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home or outpatient care settings.</brief_summary>
	<brief_title>Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Only patients having signed the consent form regarding study information, data transfer and data use The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of Ldopa or another oral iPD drug and Neupro® for at least one month The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater) The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study Patients not fulfilling the inclusion criteria And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Parkinson</keyword>
	<keyword>Treatment preference</keyword>
	<keyword>Care-giving</keyword>
</DOC>